BIOPHARM, Algerian pharmaceutical laboratory, is an industrial and commercial group which has invested at the beginning of the 1990s in the pharmaceutical sector and which today has a production unit conform to international standards and a distribution network to wholesalers and pharmacies.
After nearly two decades of intense activity, BIOPHARM achieves an important stage of its development which required reorganization
BIOPHARM adapts gradually its organizational structure as a group around its different occupations:
- The production of drug across Biopharm, which remains the core of the Group;
- The wholesale distribution of pharmaceutical products through Biopharm distribution;
- The distribution to pharmacies through BIOPURE;
- Promotion and information Medical, through HHI (Human Health Information);
- The logistics for the pharmaceutical industry through Biopharm LOGISTIC.
In addition, and in order to ensure its development and strengthen its governance and managerial skills, BIOPHARM has opened its capital to an international consortium. This formula of association encourages and committed, at the same time, the partners in the long-term development of the Group. The Consortium is composed of:
*ADPI, a specialist investment fund on the African continent, advised by Development Partners International LLP ("IPRS"), a management company of private equity funds based in London. DPI is one of the leaders in the industry of Private Equity in Africa and manages funds of Private Equity of a total amount of more than 1.1 billion US dollars. ADPI has for vocation to acquire stakes in companies in Africa and leaders on their markets.
*DEG, a subsidiary of the KfW is one of the most major European institutions for the development and financing of long-term projects and business financing. DEG invests in profitable projects that contribute to sustainable development in all sectors of 'economy, ‘agriculture, infrastructure and manufacturing services. Up to day, DEG has worked with more than 1 600 companies and its current portfolio consists of more than 5.6 billion ‘euro of participations has helped to generate a volume of ‘overall investment of 39 billion'euros.
CMF COFARES, vehicle of investment held by two institutional funds specialized on the North Africa: EuroMena funds and Mediterrania Capital Partners.
This alliance has been designed to allow the group Biopharm to take advantage of the Consortium’s networks at the international level, in order to keep up the plan for the development of its upstream and downstream activities, ensure a transfer of technology, strengthen the managerial framework and benefit from the experience of the members of the consortium to develop its export markets in Africa and in Europe.
By these actions, the Group Biopharm intends to guarantee to all its partners a strong growth of its activities, through the achievement of its ambitious program of development and in the respect of the financial security which has always characterized its management.